STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal:

Journal of Clinical Oncology

Published:

2025-12-02

DOI:

10.1200/jco-25-01204

Affiliations:

34

Authors:

29

Go to article

Institutions	Authors	Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)	2.000000	0.07
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.03
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)	1.000000	0.03
The Royal Marsden Hospital (Surrey), United Kingdom (UK)	1.000000	0.03
OhioHealth, United States of America (USA)	1.000000	0.03
UCSF Health, United States of America (USA)	1.000000	0.03
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States of America (USA)	1.000000	0.03
IRCCS Carlo Besta Neurological Institute, Italy	1.000000	0.03
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.03
Massachusetts General Hospital (MGH), United States of America (USA)	1.000000	0.03
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)	1.000000	0.03
IRCCS Istituto Oncologico Veneto (IOV), Italy	1.000000	0.03
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.03
University Hospital of Regensburg (UKR), Germany	1.000000	0.03
Candiolo Cancer Institute (FPO-IRCCS), Italy	1.000000	0.03
UC San Diego Health Sciences, United States of America (USA)	1.000000	0.03
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	1.000000	0.03
Duke University Health System, United States of America (USA)	1.000000	0.03
Cleveland Clinic, United States of America (USA)	1.000000	0.03
Kaiser Permanente Sacramento Medical Center, United States of America (USA)	1.000000	0.03
Rhode Island Hospital, United States of America (USA)	1.000000	0.03
Wake Forest University (WFU), United States of America (USA)	1.000000	0.03
Mayo Clinic, United States of America (USA)	1.000000	0.03
Pharma Data Associates, United States of America (USA)	1.000000	0.03
CancerCare Manitoba (CCMB), Canada	0.500000	0.02
University of Manitoba, Canada	0.500000	0.02
University of Turin (UNITO), Italy	0.500000	0.02
A.O.U. Citta della Salute e della Scienza di Torino, Italy	0.500000	0.02
Henry Ford Hospital, HFHS, United States of America (USA)	0.500000	0.02
Wayne State University, United States of America (USA)	0.500000	0.02
New York-Presbyterian Hospital, United States of America (USA)	0.333333	0.01
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	0.333333	0.01
Herbert Irving Comprehensive Cancer Center (HICCC), United States of America (USA)	0.333333	0.01

Interested in Oncology and Carcinogenesis?